Search

Your search keyword '"Bourlon, Maria T."' showing total 230 results
Start Over Author "Bourlon, Maria T."
230 results on '"Bourlon, Maria T."'

1. Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study

Author

Fiala, Ondřej, Massari, Francesco, Basso, Umberto, Giannatempo, Patrizia, Grande, Enrique, Buti, Sebastiano, Myint, Zin W., De Giorgi, Ugo, Pichler, Renate, Grillone, Francesco, Ürün, Yüksel, Calabrò, Fabio, Bourlon, Maria T., Galli, Luca, Kanesvaran, Ravindran, Roviello, Giandomenico, Kucharz, Jakub, Rizzo, Mimma, Park, Se Hoon, Cerbone, Linda, Seront, Emmanuel, Messina, Carlo, Molina-Cerrillo, Javier, Santini, Daniele, Yano, Akihiro, Incorvaia, Lorena, Catalano, Martina, Pinto, Alvaro, Formisano, Luigi, Soares, Andrey, Facchini, Gaetano, Fornarini, Giuseppe, Poprach, Alexandr, Rebuzzi, Sara Elena, Nasso, Cecilia, Spinelli, Gian Paolo, Angel, Martin, Stellato, Marco, Tural, Deniz, Aurilio, Gaetano, Epstein, Ilana, Carrozza, Francesco, Monteiro, Fernando Sabino Marques, Benedetti, Giovanni, Büchler, Tomáš, Ortega, Cinzia, Zakopoulou, Roubini, Battelli, Nicola, Porta, Camillo, Bellmunt, Joaquin, Gupta, Shilpa, and Santoni, Matteo

Published
2024
Full Text
View/download PDF

2. Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)

Author

Santini, Daniele, Li, Haoran, Roviello, Giandomenico, Park, Se Hoon, Grande, Enrique, Kucharz, Jakub, Basso, Umberto, Fiala, Ondrej, Monteiro, Fernando Sabino Marques, Poprach, Alexandr, Buti, Sebastiano, Molina-Cerrillo, Javier, Catalano, Martina, Buchler, Tomas, Seront, Emmanuel, Ansari, Jawaher, Myint, Zin W., Ghosn, Marwan, Calabrò, Fabio, Kopp, Ray Manneh, Bhuva, Dipen, Bourlon, Maria T., Roberto, Michela, Di Civita, Mattia Alberto, Mollica, Veronica, Marchetti, Andrea, Soares, Andrey, Battelli, Nicola, Ricci, Marco, Kanesvaran, Ravindran, Bamias, Aristotelis, Porta, Camillo, Massari, Francesco, and Santoni, Matteo

Published
2024
Full Text
View/download PDF

3. Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project

Author

Rizzo, Alessandro, Monteiro, Fernando Sabino Marques, Ürün, Yüksel, Massari, Francesco, Park, Se Hoon, Bourlon, Maria T., Poprach, Alexandr, Rizzo, Mimma, Takeshita, Hideki, Giannatempo, Patrizia, Soares, Andrey, Roviello, Giandomenico, Molina-Cerrillo, Javier, Carrozza, Francesco, Abahssain, Halima, Messina, Carlo, Kopp, Ray Manneh, Pichler, Renate, Formisano, Luigi, Tural, Deniz, Atzori, Francesco, Calabrò, Fabio, Kanesvaran, Ravindran, Buti, Sebastiano, and Santoni, Matteo

Published
2024
Full Text
View/download PDF

4. Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations

Author

Incorvaia, Lorena, Monteiro, Fernando Sabino Marques, Massari, Francesco, Park, Se Hoon, Roviello, Giandomenico, Fiala, Ondřej, Myint, Zin W., Kucharz, Jakub, Molina-Cerrillo, Javier, Santini, Daniele, Buttner, Thomas, Poprach, Alexandr, Kopecky, Jindrich, Zeppellini, Annalisa, Pichler, Martin, Buchler, Tomas, Pichler, Renate, Facchini, Gaetano, Fay, Andre Poisl, Soares, Andrey, Manneh, Ray, Iezzi, Laura, Kuronya, Zsofia, Russo, Antonio, Bourlon, Maria T., Bhuva, Dipen, Ansari, Jawaher, Kanesvaran, Ravindran, Grande, Enrique, Buti, Sebastiano, and Santoni, Matteo

Published
2024
Full Text
View/download PDF

6. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

Author

Choueiri, Toni K, Albiges, Laurence, Barthélémy, Philippe, Iacovelli, Roberto, Emambux, Sheik, Molina-Cerrillo, Javier, Garmezy, Benjamin, Barata, Pedro, Basu, Arnab, Bourlon, Maria T, Moon, Helen, Ratta, Raffaele, McKay, Rana R, Chehrazi-Raffle, Alexander, Hammers, Hans, Heng, Daniel Y C, Braendle, Edgar, Beckermann, Kathryn E, McGregor, Bradley A, and Motzer, Robert J

Published
2024
Full Text
View/download PDF

7. Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study

Author

Massari, Francesco, Mollica, Veronica, Fiala, Ondrej, De Giorgi, Ugo, Kucharz, Jakub, Vitale, Maria Giuseppa, Molina-Cerrillo, Javier, Facchini, Gaetano, Seront, Emmanuel, Lenci, Edoardo, Bourlon, Maria T., Carrozza, Francesco, Pichler, Renate, Lolli, Cristian, Myint, Zin W., Kanesvaran, Ravindran, Torniai, Mariangela, Rescigno, Pasquale, Gomez de Liaño, Alfonso, Zakopoulou, Roubini, Buti, Sebastiano, Porta, Camillo, Grande, Enrique, and Santoni, Matteo

Published
2024
Full Text
View/download PDF

9. Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

Author

Santoni, Matteo, Massari, Francesco, Myint, Zin W., Iacovelli, Roberto, Pichler, Martin, Basso, Umberto, Kopecky, Jindrich, Kucharz, Jakub, Buti, Sebastiano, Rizzo, Mimma, Galli, Luca, Büttner, Thomas, De Giorgi, Ugo, Kanesvaran, Ravindran, Fiala, Ondřej, Grande, Enrique, Zucali, Paolo Andrea, Fornarini, Giuseppe, Bourlon, Maria T., Scagliarini, Sarah, Molina-Cerrillo, Javier, Aurilio, Gaetano, Matrana, Marc R., Pichler, Renate, Cattrini, Carlo, Büchler, Tomas, Seront, Emmanuel, Calabrò, Fabio, Pinto, Alvaro, Berardi, Rossana, Zgura, Anca, Mammone, Giulia, Ansari, Jawaher, Atzori, Francesco, Chiari, Rita, Bamias, Aristotelis, Caffo, Orazio, Procopio, Giuseppe, Bassanelli, Maria, Merler, Sara, Messina, Carlo, Küronya, Zsófia, Mosca, Alessandra, Bhuva, Dipen, Vau, Nuno, Incorvaia, Lorena, Rebuzzi, Sara Elena, Roviello, Giandomenico, Zabalza, Ignacio Ortego, Rizzo, Alessandro, Mollica, Veronica, Sorgentoni, Giulia, Monteiro, Fernando Sabino M., Montironi, Rodolfo, Battelli, Nicola, and Porta, Camillo

Published
2023
Full Text
View/download PDF

13. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

Author

Santoni, Matteo, Buti, Sebastiano, Myint, Zin W., Maruzzo, Marco, Iacovelli, Roberto, Pichler, Martin, Kopecky, Jindrich, Kucharz, Jakub, Rizzo, Mimma, Galli, Luca, Büttner, Thomas, De Giorgi, Ugo, Kanesvaran, Ravindran, Fiala, Ondřej, Grande, Enrique, Zucali, Paolo Andrea, Kopp, Ray Manneh, Fornarini, Giuseppe, Bourlon, Maria T., Scagliarini, Sarah, Molina-Cerrillo, Javier, Aurilio, Gaetano, Matrana, Marc R., Pichler, Renate, Cattrini, Carlo, Büchler, Tomas, Massari, Francesco, Seront, Emmanuel, Calabrò, Fabio, Pinto, Alvaro, Berardi, Rossana, Zgura, Anca, Mammone, Giulia, Ansari, Jawaher, Atzori, Francesco, Chiari, Rita, Bamias, Aristotelis, Caffo, Orazio, Procopio, Giuseppe, Sunela, Kaisa, Bassanelli, Maria, Ortega, Cinzia, Grillone, Francesco, Landmesser, Johannes, Milella, Michele, Messina, Carlo, Küronya, Zsófia, Mosca, Alessandra, Bhuva, Dipen, Santini, Daniele, Vau, Nuno, Morelli, Franco, Incorvaia, Lorena, Rebuzzi, Sara Elena, Roviello, Giandomenico, Soares, Andrey, Bisonni, Renato, Bimbatti, Davide, Zabalza, Ignacio Ortego, Rizzo, Alessandro, Mollica, Veronica, Sorgentoni, Giulia, Monteiro, Fernando Sabino M., Battelli, Nicola, Bracarda, Sergio, and Porta, Camillo

Published
2024
Full Text
View/download PDF

14. Women, power, and cancer: a Lancet Commission

Author

Ginsburg, Ophira, Vanderpuye, Verna, Beddoe, Ann Marie, Bhoo-Pathy, Nirmala, Bray, Freddie, Caduff, Carlo, Florez, Narjust, Fadhil, Ibtihal, Hammad, Nazik, Heidari, Shirin, Kataria, Ishu, Kumar, Somesh, Liebermann, Erica, Moodley, Jennifer, Mutebi, Miriam, Mukherji, Deborah, Nugent, Rachel, So, Winnie K W, Soto-Perez-de-Celis, Enrique, Unger-Saldaña, Karla, Allman, Gavin, Bhimani, Jenna, Bourlon, María T, Eala, Michelle A B, Hovmand, Peter S, Kong, Yek-Ching, Menon, Sonia, Taylor, Carolyn D, and Soerjomataram, Isabelle

Published
2023
Full Text
View/download PDF

15. Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma

Author

Castro-Alonso, Francisco, Beas-Lozano, Evelyn, Remolina-Bonilla, Yuly A., Flaig, Thomas W., and Bourlon, Maria T.

Subjects
Metastasis -- Drug therapy, Medical colleges, Chemotherapy, Cancer -- Drug therapy -- Chemotherapy, Health
Abstract

Platinum-based chemotherapy is the standard first-line treatment for patients with MUBC, with either cisplatin or carboplatin combinations. (1-4) In patients whose disease does not progress on chemotherapy, maintenance with avelumab [...]

Published
2023

18. A View from the past into our collective future: the oncofertility consortium vision statement.

Author

Woodruff, Teresa K, Ataman-Millhouse, Lauren, Acharya, Kelly S, Almeida-Santos, Teresa, Anazodo, Antoinette, Anderson, Richard A, Appiah, Leslie, Bader, Joy, Becktell, Kerri, Brannigan, Robert E, Breech, Lesley, Bourlon, Maria T, Bumbuliene, Žana, Burns, Karen, Campo-Engelstein, Lisa, Campos, Jacira R, Centola, Grace M, Chehin, Mauricio Barbour, Chen, Diane, De Vos, Michel, Duncan, Francesca E, El-Damen, Ahmed, Fair, Douglas, Famuyiwa, Yemi, Fechner, Patricia Y, Fontoura, Paula, Frias, Olivia, Gerkowicz, Sabrina A, Ginsberg, Jill, Gracia, Clarisa R, Goldman, Kara, Gomez-Lobo, Veronica, Hazelrigg, Brent, Hsieh, Michael H, Hoyos, Luis R, Hoyos-Martinez, Alfonso, Jach, Robert, Jassem, Jacek, Javed, Murid, Jayasinghe, Yasmin, Jeelani, Roohi, Jeruss, Jacqueline S, Kaul-Mahajan, Nalini, Keim-Malpass, Jessica, Ketterl, Tyler G, Khrouf, Mohamed, Kimelman, Dana, Kusuhara, Atsuko, Kutteh, William H, Laronda, Monica M, Lee, Jung Ryeol, Lehmann, Vicky, Letourneau, Joseph M, McGinnis, Lynda K, McMahon, Eileen, Meacham, Lillian R, Mijangos, Monserrat Fabiola Velez, Moravek, Molly, Nahata, Leena, Ogweno, George Moses, Orwig, Kyle E, Pavone, Mary Ellen, Peccatori, Fedro Alessandro, Pesce, Romina Ileana, Pulaski, Hanna, Quinn, Gwendolyn, Quintana, Ramiro, Quintana, Tomas, de Carvalho, Bruno Ramalho, Ramsey-Goldman, Rosalind, Reinecke, Joyce, Reis, Fernando M, Rios, Julie, Rhoton-Vlasak, Alice S, Rodriguez-Wallberg, Kenny A, Roeca, Cassandra, Rotz, Seth J, Rowell, Erin, Salama, Mahmoud, Saraf, Amanda J, Scarella, Anibal, Schafer-Kalkhoff, Tara, Schmidt, Deb, Senapati, Suneeta, Shah, Divya, Shikanov, Ariella, Shnorhavorian, Margarett, Skiles, Jodi L, Smith, James F, Smith, Kristin, Sobral, Fabio, Stimpert, Kyle, Su, H Irene, Sugimoto, Kouhei, Suzuki, Nao, Thakur, Mili, Victorson, David, Viale, Luz, Vitek, Wendy, and Wallace, W Hamish

Subjects
Fertility preservation, Oncofertility, cancer, Genetics, Paediatrics and Reproductive Medicine, Obstetrics & Reproductive Medicine
Abstract

PurposeToday, male and female adult and pediatric cancer patients, individuals transitioning between gender identities, and other individuals facing health extending but fertility limiting treatments can look forward to a fertile future. This is, in part, due to the work of members associated with the Oncofertility Consortium.MethodsThe Oncofertility Consortium is an international, interdisciplinary initiative originally designed to explore the urgent unmet need associated with the reproductive future of cancer survivors. As the strategies for fertility management were invented, developed or applied, the individuals for who the program offered hope, similarly expanded. As a community of practice, Consortium participants share information in an open and rapid manner to addresses the complex health care and quality-of-life issues of cancer, transgender and other patients. To ensure that the organization remains contemporary to the needs of the community, the field designed a fully inclusive mechanism for strategic planning and here present the findings of this process.ResultsThis interprofessional network of medical specialists, scientists, and scholars in the law, medical ethics, religious studies and other disciplines associated with human interventions, explore the relationships between health, disease, survivorship, treatment, gender and reproductive longevity.ConclusionThe goals are to continually integrate the best science in the service of the needs of patients and build a community of care that is ready for the challenges of the field in the future.

Published
2021

19. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma

Author

McGregor, Bradley, Geynisman, Daniel M., Burotto, Mauricio, Suárez, Cristina, Bourlon, Maria T., Barata, Pedro C., Gulati, Shuchi, Huo, Stephen, Ejzykowicz, Flavia, Blum, Steven I., Del Tejo, Viviana, Hamilton, Melissa, May, Jessica R., Du, Ella X., Wu, Aozhou, Kral, Pavol, Ivanescu, Cristina, Chin, Andi, Betts, Keith A., Lee, Chung-Han, Choueiri, Toni K., Cella, David, and Porta, Camillo

Published
2023
Full Text
View/download PDF

22. How to Treat Metastatic Malignant Triton Tumor in an Adolescent

Author

Melnichenko, Irina, Sargsyan, Lilit, Bedirian, Karen, Dallakyan, Davit, Gevorgyan, Artak, Aloyan, Gevorg, Harutyunyan, Artur, Davtyan, Levon, Lazaryan, Armine, Manukyan, Narek, Tamamyan, Gevorg, Papyan, Ruzanna, Crawford, E. David, and Bourlon, Maria T.

Subjects
Cancer -- Adjuvant treatment -- Prognosis -- Care and treatment, Metastasis -- Care and treatment -- Prognosis, Vincristine, Evidence-based medicine, Health
Abstract

Malignant triton tumor (MTT) is a rare, highly aggressive disease having poor prognosis, and for which no standardized treatment guidelines exist. A 16-year-old patient was diagnosed with MTT in the [...]

Published
2022

23. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

Author

Motzer, Robert J, Powles, Thomas, Burotto, Mauricio, Escudier, Bernard, Bourlon, Maria T, Shah, Amishi Y, Suárez, Cristina, Hamzaj, Alketa, Porta, Camillo, Hocking, Christopher M, Kessler, Elizabeth R, Gurney, Howard, Tomita, Yoshihiko, Bedke, Jens, Zhang, Joshua, Simsek, Burcin, Scheffold, Christian, Apolo, Andrea B, and Choueiri, Toni K

Published
2022
Full Text
View/download PDF

25. Muscle wasting assessment tools for prostate cancer

Author

Espinosa-Marrón, Alan, Rubio-Blancas, Aquiles, Quiñones-Capistran, Christian Aníbal, Camacho-Zamora, Anais, Salcedo-Grajales, Itzel, Bravo-García, Ana Paula, Bourlon, Maria T., Castillejos-Molina, Ricardo A., Dias, Julie-Alexia, and del Pilar Milke-García, María

Published
2022
Full Text
View/download PDF

26. Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study.

Author

Fiala, Ondřej, Massari, Francesco, Basso, Umberto, Giannatempo, Patrizia, Grande, Enrique, Buti, Sebastiano, Myint, Zin W., De Giorgi, Ugo, Pichler, Renate, Grillone, Francesco, Ürün, Yüksel, Calabrò, Fabio, Bourlon, Maria T., Galli, Luca, Kanesvaran, Ravindran, Roviello, Giandomenico, Kucharz, Jakub, Rizzo, Mimma, Park, Se Hoon, and Cerbone, Linda

Abstract

Background: Enfortumab vedotin (EV) has been approved for the treatment of patients with locally advanced/metastatic urothelial carcinoma (la/mUC) who previously received platinum-based chemotherapy followed by immune checkpoint inhibitors. However, the pivotal clinical trials did not include patients previously treated with avelumab maintenance therapy. Objective: The aim of the present retrospective analysis was to assess the effectiveness of EV following avelumab in patients with mUC enrolled in the ARON-2EV study. Patients and Methods: The study included 182 patients with mUC treated with EV following avelumab maintenance. The primary objective was to assess clinical outcomes, including progression-free survival (PFS), overall survival (OS), overall response rate (ORR), and duration of response (DoR). Statistical analysis involved Fisher exact test, Kaplan–Meier method, log-rank test, and univariate/multivariate Cox proportional hazard regression models. Results: Median OS and PFS were 12.7 (95% CI 10.2–14.1) and 7.9 (95% CI 6.4–9.9) months, respectively. Complete response (CR) was achieved in 5% and partial response (PR) in 34% of patients, with an ORR of 39%. The DoR in patients who achieved CR/PR was 10.9 months (95% CI 8.1–11.4). The incidence of grade ≥ 3 peripheral neuropathy and skin rash was 9%, followed by 8% of grade ≥ 3 diarrhea and 4% of grade ≥ 3 hyperglycemia. Conclusions: The results of our large international retrospective study confirm the effectiveness of EV and endorse its use in the population of patients with mUC treated with EV following the frontline platinum-based chemotherapy and subsequent maintenance treatment with avelumab. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Metastatic Renal Cell Carcinoma With Sarcomatoid Features

Author

Mateos-Soria, Abigail, Castro-Alonso, Francisco J., Sener, Yusuf Z., Quintero-Bustos, Gabriel, Licano-Zubiate, Mariana, Bourlon, Rene, Lam, Elaine T., and Bourlon, Maria T.

Subjects
Metastasis -- Development and progression, Antineoplastic agents -- Analysis, Carcinoma -- Development and progression, Cancer -- Development and progression, Antimitotic agents -- Analysis, Health
Abstract

THE CASE A previously healthy woman, aged 38 years, presented with a 3-month history of fatigue, dyspnea on exertion, significant weight loss, and severe left fl ank pain; her symptoms [...]

Published
2022

29. Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell Tumor

Author

Crawford, E. David and Bourlon, Maria T.

Subjects
Glycoproteins, Chorionic gonadotropin, Chemotherapy, Cancer -- Chemotherapy, Company business management, Health
Abstract

THE CASE An 18-year-old man presented with a one-month history of a nonpainful right testicular enlargement. He had no family history of neoplasia, nor any relevant past medical history. The [...]

Published
2021

30. Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)

Author

Santoni, Matteo, Massari, Francesco, Myint, Zin W., Iacovelli, Roberto, Pichler, Martin, Basso, Umberto, Kopecky, Jindrich, Kucharz, Jakub, Buti, Sebastiano, Salfi, Alessia, Büttner, Thomas, De Giorgi, Ugo, Kanesvaran, Ravindran, Fiala, Ondřej, Grande, Enrique, Zucali, Paolo Andrea, Fornarini, Giuseppe, Bourlon, Maria T, Scagliarini, Sarah, Molina-Cerrillo, Javier, Aurilio, Gaetano, Matrana, Marc R, Pichler, Renate, Cattrini, Carlo, Büchler, Tomas, Seront, Emmanuel, Calabrò, Fabio, Pinto, Alvaro, Berardi, Rossana, Zgura, Anca, Mammone, Giulia, Ansari, Jawaher, Atzori, Francesco, Chiari, Rita, Zakopoulou, Roubini, Caffo, Orazio, Procopio, Giuseppe, Bassanelli, Maria, Zampiva, Ilaria, Messina, Carlo, Küronya, Zsófia, Mosca, Alessandra, Bhuva, Dipen, Vau, Nuno, Incorvaia, Lorena, Rebuzzi, Sara Elena, Roviello, Giandomenico, Zabalza, Ignacio Ortego, Rizzo, Alessandro, Mollica, Veronica, Catalini, Ilaria, Monteiro, Fernando Sabino M., Montironi, Rodolfo, Battelli, Nicola, Rizzo, Mimma, and Porta, Camillo

Published
2023
Full Text
View/download PDF

31. Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic Melanoma

Author

Sobrevilla-Moreno, Nora, Rivera-Sanchez, Daniel, Garcia-Ortega, Dorian Y., Lopez-Macias, Diego, Garcilazo-Reyes, Alexandra, Alvarez-Avitia, Miguel A., Crawford, E. David, and Bourlon, Maria T.

Subjects
Metastasis -- Drug therapy, Antineoplastic agents, Immunotherapy, Cancer -- Care and treatment, Radiotherapy, Antimitotic agents, Health
Abstract

Which of the following is true about the treatment of oligoprogressive disease in patients with metastatic melanoma? A. Time from surgery to recurrence does not affect the benefit of a [...]

Published
2021

35. Sjogren Syndrome Induced by Immune Checkpoint Inhibitors in a Patient with Advanced Renal Cell Carcinoma

Author

Conde-Flores, Emilio, Remolina-Bonilla, Yuly A., Castro-Alonso, Francisco J., Martinez-Ibarra, Nayeli A., Hernandez-Molina, Gabriela, Chapa-Ibarguengoitia, Monica, Gamboa-Dominguez, Armando, and Bourlon, Maria T.

Subjects
Hemoglobin, Ipilimumab, Metastasis, B cells, Smoking, Carcinoma, Renal cell, Health
Abstract

THE CASE A Mexican man, aged 77 years, presented to the oncology clinic with a sternal mass. His past medical history was relevant for tobacco use for a 50 pack-year [...]

Published
2021

36. Advanced Penile Cancer Presenting With Renal Failure

Author

Crawford, E. David, Bourlon, Maria T., Derby, Sarah, Wallace, Jan, Venugopal, Balaji, and Garcia, Maria Almudena Cascales

Subjects
Blood -- Medical examination, Fatigue -- Development and progression, Penis, Cancer -- Development and progression, Evidence-based medicine, Health
Abstract

THE CASE 'MK,' a man aged 67 years, presented with fatigue and nausea to his primary care physician. Routine blood tests showed a stage III acute kidney injury and the [...]

Published
2021

38. Hand-Foot Skin Reaction Secondary to Sunitinib in a Patient With Metastatic Clear Cell Renal Cell Carcinoma

Author

Ferez-Blando, Karen, Castro-Alonso, Francisco J., Dominguez-Cherit, Judith, and Bourlon, Maria T.

Subjects
Antineoplastic agents -- Health aspects, Metastasis -- Health aspects, Carcinoma -- Health aspects, Skin -- Health aspects, Cancer -- Health aspects, Antimitotic agents -- Health aspects, Health
Abstract

THE CASE A man, age 45 years, was diagnosed with intermediate-risk stage IV clear cell renal carcinoma (lung and lymph node metastases). He was prescribed first-line systemic treatment with sunitinib [...]

Published
2021

40. Pediatric Locally Advanced Synovial Sarcoma: What Would Be the Best Treatment Option?

Author

Crawford, E. David, Bourlon, Maria T., Petrosyan, Meri, Avagyan, Anna, Mesrobian, Arianna, Hovsepyan, Shushan, Koloyan, Zaven, Tamamyan, Gevorg, and Papyan, Ruzanna

Subjects
Pediatrics, Health
Abstract

THE CASE A female patient, age 11 years, presented with a firm, palpable mass in the left lower quadrant of the abdomen. Upon ultrasound imaging, the 3.5 cm * 5 [...]

Published
2021

41. Differences in the expression of the phosphatase PTP-1B in patients with localized prostate cancer with and without adverse pathological features.

Author

Bourlon, Maria T., Urbina-Ramirez, Shaddai, Verduzco-Aguirre, Haydee C., Mora-Pineda, Mauricio, Velazquez, Hugo E., Leon-Rodriguez, Eucario, Atisha-Fregoso, Yemil, and De Anda-Gonzalez, María G.

Subjects
PROSTATE cancer patients, PROSTATE cancer, PROSTATE-specific antigen, TYPE 2 diabetes, IMMUNOSTAINING, PROTEIN-tyrosine phosphatase
Abstract

Introduction: Patients with adverse pathological features (APF) at radical prostatectomy (RP) for prostate cancer (PC) are candidates for adjuvant treatment. Clinicians lack reliable markers to predict these APF preoperatively. Protein tyrosine phosphatase 1B (PTP-1B) is involved in migration and invasion of PC, and its expression could predict presence of APF. Our aim was to compare PTP-1B expression in patients with and without APF, and to explore PTP-1B expression as an independent prognostic factor. Methods: Tissue microarrays (TMAs) were constructed using RP archival specimens for immunohistochemical staining of PTP-1B; expression was reported with a standardized score (0-9). We compared median PTP-1B score between cases with and without APF. We constructed two logistic regression models, one to identify the independence of PTP-1B score from biologically associated variables (metformin use and type 2 diabetes mellitus [T2DM]) and the second to seek independence of known risk factors (Gleason score and prostate specific antigen [PSA]). Results: A total of 73 specimens were suitable for TMA construction. Forty-four (60%) patients had APF. The median PTP-1B score was higher in those with APF: 8 (5-9) vs 5 (3-8) (p=0.026). In the logistic regression model including T2DM and metformin use, the PTP-1B scoremaintained statistical significance (OR 1.21, 95% CI 1.01-1.45, p=0.037). In the model including PSA and Gleason score; the PTP-1B score showed no independence (OR 1.68, 95% CI 0.97-1.41, p=0.11). The area under the curve to predict APF for the PTP-1B score was 0.65 (95% CI 0.52-0.78, p=0.03), for PSA+Gleason 0.71 (95% CI 0.59-0.82, p=0.03), and for PSA+Gleason+PTP-1B score 0.73 (95% CI 0.61-0.84, p=0.001). Discussion: Patients with APF after RP have a higher expression of PTP-1B than those without APF, even after adjusting for T2DM and metformin exposure. PTP-1B has a good accuracy for predicting APF but does not add to known prognostic factors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Impact of healthcare inequities on survival in Mexican patients with metastatic renal cell carcinoma

Author

Bourlon, Maria T., primary, Remolina-Bonilla, Yuly A., additional, Acosta-Medina, Aldo A., additional, Saldivar-Oviedo, Bruno I., additional, Perez-Silva, Antonio, additional, Martinez-Ibarra, Nayeli, additional, Castro-Alonso, Francisco Javier, additional, Martín-Aguilar, Ana E., additional, Rivera-Rivera, Samuel, additional, Mota-Rivero, Fernando, additional, Pérez-Pérez, Perla, additional, Díaz-Alvarado, María G., additional, Ruiz-Morales, José M., additional, Campos-Gómez, Saúl, additional, Martinez-Cannon, Bertha Alejandra, additional, Lam, Elaine T., additional, and Sobrevilla-Moreno, Nora, additional

Published
2023
Full Text
View/download PDF

43. Disorders of Sex Development and Malignant Germ Cell Tumors

Author

Araujo-Melendez, Miguel, Verduzco-Aguirre, Haydee, Morales, Juan J., Martinez-Benitez, Braulio, Castillejos-Molina, Ricardo, Fuentes, Alejandro, Salama, Mahmoud, and Bourlon, Maria T.

Subjects
Medical research, Medicine, Experimental, Tumors, Reproductive organs, Hernia, Health
Abstract

THE CASE A woman, aged 44 years, presented at the general oncology outpatient clinic with bloating, abdominal pain, and significant unintended weight loss. Her past medical history included a bilateral [...]

Published
2020

44. Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic

Author

Crawford, E. David, Carril-Ajuria, Lucia, Remolina-Bonilla, Yuly A., Carretero-Gonzalez, Alberto, Martin-Soberon, Maricruz, Castellano, Daniel, Bourlon, Christianne, de Velasco, Guillermo, and Bourlon, Maria T.

Subjects
Prostate cancer -- Care and treatment, Cancer patients -- Care and treatment, Chronic kidney failure -- Care and treatment, Zoledronic acid, Chemotherapy, Cancer -- Chemotherapy, Coronaviruses, Health
Abstract

THE CASE A 78-year-old man had a medical history of hypertension, atrial fibrillation, chronic kidney disease, and metastatic castration-resistant prostate cancer (CRPC). He had progressed to first-line therapy for CRPC [...]

Published
2020

45. Which Larynx-Preservation Strategy Would Be Best for a Patient With Resectable, Locally Advanced, Hypopharynx Squamous Cell Carcinoma?

Author

Crawford, E. David, Bourlon, Maria T., Sobrevilla-Moreno, Nora, Altamirano-Garcia, Javier I., Granados-Garcia, Martin, Garcilazo-Reyes, Alexandra, Herrera-Martinez, Marytere, and Alvarez-Avitia, Miguel A.

Subjects
Carboplatin, Squamous cell carcinoma -- Care and treatment, Pain -- Care and treatment, Health
Abstract

THE CASE A 57-year-old man with a heavy smoking and alcohol consumption history, but no comorbidities, presented with pharyngeal pain to his primary care physician's office. He received empirical treatment [...]

Published
2020

46. Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus Ipilimumab

Author

Remolina-Bonilla, Yuly A., Jimenez-Franco, Brenda, Lam, Elaine T., and Bourlon, Maria T.

Subjects
Ipilimumab -- Complications and side effects, Immunotherapy, Medical laboratories, Health
Abstract

THE CASE A 56-year-old white man with a 74 pack-year smoking history presented with macroscopic hematuria and a significant weight loss of 45 pounds in 6 months. His clinical laboratory [...]

Published
2020

47. Hypercalcemia in a Patient with Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia

Author

Crawford, E. David, Bourlon, Maria T., Copur, Mehmet Sitki, Wedel, Whitney, Jonglertham, Pornchai, Springer, Carlene, and Horn, Adam

Subjects
Hemoglobin -- Health aspects, Anemia -- Development and progression, Blood cell count -- Health aspects, Antineoplastic agents -- Health aspects, Non-Hodgkin's lymphomas -- Development and progression, Lymphocytic leukemia -- Development and progression, Antimitotic agents -- Health aspects, Health
Abstract

THE CASE A 64-year-old white man was originally diagnosed with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) back in 2007. Initial presentation was with fatigue, elevated white blood cell counts [...]

Published
2019

48. Emergency Fertility Preservation in a Young Woman With Non-Hodgkin Lymphoma

Author

Crawford, E. David, Bourlon, Maria T., Salama, Mahmoud, Isachenko, Evgenia, Rahimi, Gohar, Mallmann, Peter, and Isachenko, Vladimir

Subjects
Non-Hodgkin's lymphomas, Vincristine, Chemotherapy, Cancer -- Chemotherapy, Health
Abstract

THE CASE A nulliparous woman, age 25 years, had received a diagnosis of non-Hodgkin lymphoma (NHL) and now presented with stage IIA diffuse large B-cell lymphom a (DLBCL). According to [...]

Published
2021

49. Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations

Author

PORTA, Camillo, primary, BAMIAS, Aristotelis, additional, ZAKOPOULOU, Roubini, additional, MYINT, Zin W., additional, CAVASIN, Nicolò, additional, IACOVELLI, Roberto, additional, PICHLER, Martin, additional, KOPECKY, Jindrich, additional, KUCHARZ, Jakub, additional, RIZZO, Mimma, additional, GALLI, Luca, additional, BÜTTNER, Thomas, additional, DE GIORGI, Ugo, additional, KANESVARAN, Ravindran, additional, FIALA, Ondřej, additional, GRANDE, Enrique, additional, ZUCALI, Paolo A., additional, KOPP, Ray M., additional, FORNARINI, Giuseppe, additional, BOURLON, Maria T., additional, SCAGLIARINI, Sarah, additional, MOLINA-CERRILLO, Javier, additional, AURILIO, Gaetano, additional, MATRANA, Marc R., additional, PICHLER, Renate, additional, CATTRINI, Carlo, additional, BÜCHLER, Tomáš, additional, MASSARI, Francesco, additional, MOLLICA, Veronica, additional, SERONT, Emmanuel, additional, CALABRÒ, Fabio, additional, PINTO, Alvaro, additional, BERARDI, Rossana, additional, ZGURA, Anca, additional, MAMMONE, Giulia, additional, ANSARI, Jawaher, additional, ATZORI, Francesco, additional, CHIARI, Rita, additional, CAFFO, Orazio, additional, PROCOPIO, Giuseppe, additional, SUNELA, Kaisa, additional, BASSANELLI, Maria, additional, ORTEGA, Cinzia, additional, GRILLONE, Francesco, additional, LANDMESSER, Johannes, additional, MERLER, Sara, additional, MESSINA, Carlo, additional, KÜRONYA, Zsófia, additional, MOSCA, Alessandra, additional, BHUVA, Dipen, additional, SANTINI, Daniele, additional, VAU, Nuno, additional, MORELLI, Franco, additional, INCORVAIA, Lorena, additional, REBUZZI, Sara E., additional, ROVIELLO, Giandomenico, additional, SOARES, Andrey, additional, ZABALZA, Ignacio O., additional, RIZZO, Alessandro, additional, BISONNI, Renato, additional, PIERANTONI, Francesco, additional, SORGENTONI, Giulia, additional, MONTEIRO, Fernando S., additional, BATTELLI, Nicola, additional, BUTI, Sebastiano, additional, and SANTONI, Matteo, additional

Published
2023
Full Text
View/download PDF

50. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

Author

Santoni, Matteo, primary, Buti, Sebastiano, additional, Myint, Zin W., additional, Maruzzo, Marco, additional, Iacovelli, Roberto, additional, Pichler, Martin, additional, Kopecky, Jindrich, additional, Kucharz, Jakub, additional, Rizzo, Mimma, additional, Galli, Luca, additional, Büttner, Thomas, additional, De Giorgi, Ugo, additional, Kanesvaran, Ravindran, additional, Fiala, Ondřej, additional, Grande, Enrique, additional, Zucali, Paolo Andrea, additional, Kopp, Ray Manneh, additional, Fornarini, Giuseppe, additional, Bourlon, Maria T., additional, Scagliarini, Sarah, additional, Molina-Cerrillo, Javier, additional, Aurilio, Gaetano, additional, Matrana, Marc R., additional, Pichler, Renate, additional, Cattrini, Carlo, additional, Büchler, Tomas, additional, Massari, Francesco, additional, Seront, Emmanuel, additional, Calabrò, Fabio, additional, Pinto, Alvaro, additional, Berardi, Rossana, additional, Zgura, Anca, additional, Mammone, Giulia, additional, Ansari, Jawaher, additional, Atzori, Francesco, additional, Chiari, Rita, additional, Bamias, Aristotelis, additional, Caffo, Orazio, additional, Procopio, Giuseppe, additional, Sunela, Kaisa, additional, Bassanelli, Maria, additional, Ortega, Cinzia, additional, Grillone, Francesco, additional, Landmesser, Johannes, additional, Milella, Michele, additional, Messina, Carlo, additional, Küronya, Zsófia, additional, Mosca, Alessandra, additional, Bhuva, Dipen, additional, Santini, Daniele, additional, Vau, Nuno, additional, Morelli, Franco, additional, Incorvaia, Lorena, additional, Rebuzzi, Sara Elena, additional, Roviello, Giandomenico, additional, Soares, Andrey, additional, Bisonni, Renato, additional, Bimbatti, Davide, additional, Zabalza, Ignacio Ortego, additional, Rizzo, Alessandro, additional, Mollica, Veronica, additional, Sorgentoni, Giulia, additional, Monteiro, Fernando Sabino M., additional, Battelli, Nicola, additional, Bracarda, Sergio, additional, and Porta, Camillo, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results